These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 37848682

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, Liu G, Yang M, Gu J, Cui X, Pan Y, Tian X.
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [Abstract] [Full Text] [Related]

  • 5. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
    Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.
    J Clin Invest; 2016 Aug 01; 126(8):3130-44. PubMed ID: 27454297
    [Abstract] [Full Text] [Related]

  • 6. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis.
    Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, Jiang Z, Wu Q, Long Y, Wang S, Tang Z, Pan H, Li X, Wei W, Yang J, Luo X, Zhang Z, Tang Q, Liu P, Weinkove R, Yao Y, Qin D, Thiery JP, Li P.
    Nat Commun; 2022 Oct 13; 13(1):6051. PubMed ID: 36229619
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S.
    Front Immunol; 2018 Oct 13; 9():1955. PubMed ID: 30214445
    [Abstract] [Full Text] [Related]

  • 9. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT.
    Cytotherapy; 2023 Feb 13; 25(2):148-161. PubMed ID: 36396553
    [Abstract] [Full Text] [Related]

  • 10. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
    Lee HJ, Hwang SJ, Jeong EH, Chang MH.
    J Microbiol; 2024 Jul 13; 62(7):555-568. PubMed ID: 38700775
    [Abstract] [Full Text] [Related]

  • 11. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W.
    Clin Cancer Res; 2021 Jan 15; 27(2):473-484. PubMed ID: 33028589
    [Abstract] [Full Text] [Related]

  • 12. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN, Rietberg SP, Bonifant CL.
    Cytotherapy; 2018 Oct 15; 20(10):1259-1266. PubMed ID: 30309710
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A, Hawk W, Nylen E, Ober S, Autin P, Barber A.
    Immunology; 2017 Nov 15; 152(3):472-483. PubMed ID: 28670716
    [Abstract] [Full Text] [Related]

  • 16. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, Yenchitsomanus PT.
    Biomed Pharmacother; 2023 Dec 15; 168():115691. PubMed ID: 37844355
    [Abstract] [Full Text] [Related]

  • 17. Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland.
    Vizcaya D, Farahmand B, Walter AO, Kneip C, Jöhrens K, Tukiainen M, Schmitz AA.
    Cancer Treat Res Commun; 2020 Dec 15; 25():100260. PubMed ID: 33310366
    [Abstract] [Full Text] [Related]

  • 18. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
    Susek KH, Schwietzer YA, Karvouni M, Gilljam M, Keszei M, Hussain A, Lund J, Kashif M, Lundqvist A, Ljunggren HG, Nahi H, Wagner AK, Alici E.
    Cancer Immunol Immunother; 2023 May 15; 72(5):1153-1167. PubMed ID: 36355079
    [Abstract] [Full Text] [Related]

  • 19. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ, Bailey CG, Nagarajah R, Liang O, Metierre C, Sagnella SM, Castelletti L, Yeo D, Adelstein S, Rasko JEJ.
    Cytotherapy; 2024 Apr 15; 26(4):325-333. PubMed ID: 38349311
    [Abstract] [Full Text] [Related]

  • 20. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G, Zhang Q, Liu G, Li D, Zhang L, Gu Z, Tian H, Zhang Y, Tian X.
    Exp Cell Res; 2021 Dec 01; 409(1):112886. PubMed ID: 34673000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.